Fedorovskaia N A, Istomina L A, Kopaneva T G, Iugov Iu I, Timkina E N, Minakov V N, Kudriavtseva A V
Ter Arkh. 1997;69(4):61-4.
Low course doses of cyclophosphamide (1.9 +/- 0.2 g) were given to postsplenectomy patients with grave aplastic anemia (GAA). A total of 27 patients aged 14-42 years were treated, 27 control GAA patients did not receive cyclophosphamide. The cyclophosphamide therapy was controlled by T-lymphocyte functional activity assessed in active rosette formation test with levamisole in vitro. 19 (70.3%) patients were treated twice. The remission was achieved in 22 patients (81.5%), partial response was in 1 patient (3.7%), 4 patients died (14.8%). In control subjects the remission was recorded only in 4 subjects, 23 patients died 3 to 12 months after splenectomy. It is evident that low-dose courses of cyclophosphamide are highly effective in case of control over immunological activity of the pathological process.
对患有严重再生障碍性贫血（GAA）的脾切除术后患者给予低疗程剂量的环磷酰胺（1.9±0.2克）。共治疗了27例年龄在14至42岁之间的患者，27例对照GAA患者未接受环磷酰胺治疗。环磷酰胺治疗通过在体外使用左旋咪唑进行活性玫瑰花结形成试验评估T淋巴细胞功能活性来控制。19例（70.3%）患者接受了两次治疗。22例患者（81.5%）实现缓解，1例患者（3.7%）部分缓解，4例患者死亡（14.8%）。在对照受试者中，仅4例受试者出现缓解，23例患者在脾切除术后3至12个月死亡。显然，在控制病理过程的免疫活性方面，低剂量疗程的环磷酰胺非常有效。
